Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Senxuan Pharmaceutical CoBJSE:920946 86 Return-on-Tangible-Equity is 13.67% as of Jun. 2026, which is 9% below its 10-year median of 15.00. GuruFocus rates BJSE:920946 with a GF Score™ of 86/100 and a GF Value™ of ¥10.80 (Fairly Valued). The stock has 2 warning signs investors should review. Among 896 Drug Manufacturers companies, Jiangsu Senxuan Pharmaceutical Co ranks better than 62.95% on this metric.
The historical rank and industry rank for Jiangsu Senxuan Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:
BJSE:920946'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.98 Med: 15 Max: 33.46
Current: 12.54
During the past 13 years, Jiangsu Senxuan Pharmaceutical Co's highest Return-on-Tangible-Equity was 33.46%. The lowest was 10.98%. And the median was 15.00%.
BJSE:920946's Return-on-Tangible-Equity is ranked better than 62.95% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.575
vs BJSE:920946: 12.54
Jiangsu Senxuan Pharmaceutical Co (BJSE:920946) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Jiangsu Senxuan Pharmaceutical Co Return-on-Tangible-Equity Related Terms
Jiangsu Senxuan Pharmaceutical Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Senxuan Pharmaceutical Co Return-on-Tangible-Equity Chart
BJSE:920946 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Senxuan Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Senxuan Pharmaceutical Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Senxuan Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Jiangsu Senxuan Pharmaceutical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 13.67% mean?
Jiangsu Senxuan Pharmaceutical Co (BJSE:920946) has a Return-on-Tangible-Equity of 13.67% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jiangsu Senxuan Pharmaceutical Co and its competitors. This is near median its historical median of 15.00. Over the past decade, Jiangsu Senxuan Pharmaceutical Co's Return-on-Tangible-Equity has ranged from 10.98 to 33.46. According to the industry distribution chart, Jiangsu Senxuan Pharmaceutical Co ranks #332 out of 896 companies in the Drug Manufacturers industry, placing it in the top 37.1%.
Is Jiangsu Senxuan Pharmaceutical Co's Return-on-Tangible-Equity too high?
Jiangsu Senxuan Pharmaceutical Co's current Return-on-Tangible-Equity of 13.67% is near median its 10-year median of 15.00. Over the past 10 years, this metric has ranged from a low of 10.98 to a high of 33.46. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.58. Jiangsu Senxuan Pharmaceutical Co's value of 13.67% is 80.5% above this industry median. Based on the distribution chart, Jiangsu Senxuan Pharmaceutical Co ranks #332 out of 896 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jiangsu Senxuan Pharmaceutical Co has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Senxuan Pharmaceutical Co's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jiangsu Senxuan Pharmaceutical Co ranks #332 out of 896 companies for Return-on-Tangible-Equity. This puts Jiangsu Senxuan Pharmaceutical Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.58. Jiangsu Senxuan Pharmaceutical Co's value of 13.67% is 80.5% above this benchmark. Historically, Jiangsu Senxuan Pharmaceutical Co's own Return-on-Tangible-Equity has ranged from 10.98 to 33.46 over the past decade. While the company's 10-year median is 15.00 vs. the industry median of 7.58, Jiangsu Senxuan Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.58, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Senxuan Pharmaceutical Co's current Return-on-Tangible-Equity of 13.67% is 80.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jiangsu Senxuan Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Senxuan Pharmaceutical Co's current Return-on-Tangible-Equity is 13.67%, which is near median its own 10-year median of 15.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Senxuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Senxuan Pharmaceutical Co (BJSE:920946) is currently considered Fairly Valued. The stock's GF Value™ is ¥10.80, compared to a current price of ¥10.05 — trading 6.9% below its estimated fair value. The current Return-on-Tangible-Equity is 13.67%, which is near median its 10-year median of 15.00 and 80.5% above the Drug Manufacturers industry median of 7.58. Jiangsu Senxuan Pharmaceutical Co's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Jiangsu Senxuan Pharmaceutical Co (BJSE:920946), the current Return-on-Tangible-Equity is 13.67% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Senxuan Pharmaceutical Co (BJSE:920946) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Senxuan Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥10.05 is trading 6.9% below its estimated GF Value™ of ¥10.80.
GuruFocus considers Jiangsu Senxuan Pharmaceutical Co to be Fairly Valued.
Key valuation signals for BJSE:920946:
Return-on-Tangible-Equity: 13.67% (near median its 10-year median of 15.00)
GF Value™: ¥10.80 vs. price of ¥10.05 (6.9% below fair value)
Industry Position: 80.5% above the Drug Manufacturers median (#332 of 896)
No single metric tells the full story. See the BJSE:920946 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Senxuan Pharmaceutical Co Ltd is involved in the R&D, production, and sales of pharmaceutical intermediates and chemical intermediates. The company's main business is the research and development, production, and sales of raw materials and pharmaceutical intermediates.
86GF Score
Get the complete analysis for BJSE:920946
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920946 has been successfully added to your 
